Skip to main content
OpenTrials

Clinical trial condition

Neoplastic Processes

Explore clinical trials studying Neoplastic Processes. Study availability and eligibility vary by location and protocol.

3,272 public trials 686 recruiting studies
Refine in advanced search Browse all conditions

Neoplastic Processes trial results

Completed

Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors

NCT03517956

Conditions
Advanced or Metastatic Solid Tumor, Neoplasm Metastasis, Neoplasms, +3 more
Locations
  • USC Norris Hospital and Clinics Los Angeles, California, United States
  • Northwestern University Chicago, Illinois, United States
  • University of Maryland Baltimore, Maryland, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View all 20 locations
View Trial Details
Completed

A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer

NCT04087174

Conditions
Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +12 more
Locations
  • Research Site Indianapolis, Indiana, United States
  • Research Site Omaha, Nebraska, United States
  • Research Site White Plains, New York, United States
  • Research Site Gettysburg, Pennsylvania, United States
View Trial Details
Completed

A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer

NCT03042611

Conditions
Digestive System Diseases, Digestive System Neoplasms, Gastric Adenocarcinoma, +11 more
Locations
  • Mayo Clinic Phoenix Scottsdale, Arizona, United States
  • Highlands Oncology Group Rogers, Arkansas, United States
  • Karmanos Cancer Institute Detroit, Michigan, United States
  • Mayo Clinic Cancer Center Rochester, Minnesota, United States
View all 95 locations
View Trial Details
Completed

First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody)

NCT03852511

Conditions
Carcinoma, Epithelial Tumor, Infections, +9 more
Locations
  • University of California, Los Angeles (UCLA) Santa Monica, California, United States
  • University of Colorado Aurora, Colorado, United States
  • Memorial Sloan Kettering Cancer Center (MSKCC) New York, United States
  • Cleveland Clinic Cleveland, Ohio, United States
View Trial Details

Related conditions